Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Rounds Report: Eleven Biotherapeutics Traded Further North While Cerecor Experienced Heavy Insider Accumulation

|Includes: AZN, IBB, Sesen Bio, Inc. (SESN), XBI
Summary

The overall bioscience market traded down due to negative sentiment.

Despite a down day, the shares of Eleven Biotherapeutics moved further North.

The upcoming clinical binary can catapult the stock much higher. Conversely, it can tumble in the case of a negative event.

Cerecor experienced substantial insider purchases and is worth a second look. FDA’s increased budget is reflective of the tireless due diligence in delivering more therapeutics to Americans while protecting consumers health.

This is preview sample of the Integrated BioSci Rounds Report published in advanced and exclusively for subscribers of Integrated BioSci Investing.

Almost all good businesses engage in pain today for gain tomorrow activities. - Charlie Munger

Trading Analytics

Welcome to another edition of Integrated BioSci Rounds Report for April 24, 2018. As usual, we’ll elucidate notable trading analytics for the day, recent insider transactions, and interesting developments. Without further ado, let’s assess the overall market performance. As follows, the iShares of NASDAQ Biotechnology Index (NASDAQ:IBB) traded down by $1.52 (-1.45%) at $103.27. Moreover, the SPDR S&P Biotech (NYSE:XBI) exchanged hands $1.61 lower at $86.45 (for -1.83% losses). It’s likely that investors were trading with extreme negative sentiment for the day. Regardless of the daily inclination, there are substantial prospects in the bioscience sector: one that delivers hope for patients while rewarding supporters with substantial wealth in the long haul.

Figure 1: Notable BioSci movers. (Source: Morningstar).

Next up is Eleven Biotherapeutics (NASDAQ:EBIO), a company focusing on the innovation and commercialization of the novel molecules, Targeted Protein Therapeutics (“TPTs”). Following the strong momentum from yesterday, the stock added another $0.13 to close the session at $2.22 (for over 6% profits).

TPT is a fusion drug - having an antibody linked to a (cytotoxic) protein payload. Designed for the localized cancer destruction, the antibody helps to zone in on specific cancer cells while the cytotoxic protein is used to kill rogue tumors. Notably, TPT can be employed as either a promising single drug or in combinations with other immuno-oncology agents such as checkpoint inhibitors.

Back on Sept. 2017, Elevent commenced a trial at the US National Cancer Institute (“NCI”) - to assessing Vicinium combo with AstraZeneca (NYSE:AZN)’s immune checkpoint inhibitor, Imfinzi for high-grade non-muscle invasive bladder cancer (“NMIBC”). If the data will turn out robust as we prognosticated, the company can become a target of acquisition by AstraZeneca.

In addition, the VISTA trial studying Vicinium (a protein coupled with antibody to attack EpCAM positive tumors) designed as a potential treatment of NMIBC will report the topline results in several months. There is a favorable chance that this clinical binary to post positive outcomes to catapult the shares over 80%. However, there is also the risk that the shares can tumble by similar the magnitude.

Final Remarks

This is a preview of the Integrated BioSci Rounds Report that was published in advanced and exclusively for subscribers of Integrated BioSci Investing. Of note, we periodically send out a completely FREE Integrated BioSci Research to people in Dr. Tran BioSci's mailing list. Be sure to sign up for our mailing list HERE to not miss a single article.

We Invite you to try our FREE 2-week trial (and, to lock in the current price to save money for the future).

Author’s Notes: We’re honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI”) marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics (NASDAQ:NKTR) procured more than 349% profits; Spectrum Pharmaceuticals (NASDAQ:SPPI) delivered over 125% gains; Kite Pharma netted 83%; Atara Biotherapeutics (NASDAQ:ATRA) appreciated +186%. Crispr Therapeutics (NASDAQ:CRSP) garned plus 141%. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.

Notably, we’ll increase our price soon. SUBSCRIBE to our marketplace research now to lock in the current price and save money in the future. To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and CLICK the orange FOLLOW button . Asides the exclusivities, this article is the truncated version of the research we published in advance to IBI subscribers. Further, you can read up on Dr. Tran’s background by followingthis link. If you'd like to get our other once weekly ideas sent to your mailbox, check out Dr. Tran BioSci and sign up with our mailing list.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.